TABLE 2.
Amino acid substitutions in the HIV-1 protease sequences of isolates from 142 treatment-naive patients at key positions associated with resistance to available drugs
| Subtype | No. of strains | Mutation(s) in the protease at key positions in the following wild-type amino acids and positions:
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| L10 | K20 | L33 | M36 | M46 | L63 | A71 | V77 | V82 | ||
| A | 9 | I3a, V1 | R1, I1 | I9 | P1, Q1 | |||||
| B | 13 | P6, S1, H1 | I3 | |||||||
| C | 2 | R1 | I2 | T1, S1 | ||||||
| D | 5 | V1 | I3 | P1, S1 | ||||||
| F1 + F2 | 11 | V4 | R8, I1 | I11 | I1 | P3, T2, S1, V1 | ||||
| G | 4 | I1 | I4 | I4 | P1 | I4 | ||||
| K | 2 | I1, V1 | R2 | I2 | C1 | |||||
| J | 5 | I2, V1 | I3 | T2, I1 | I1 | |||||
| CRF02-AG | 67 | I3, V6 | M1, I63, V2 | F1 | I67 | P2, S3, F1, V1, I3, N1 | I4 | I3 | ||
| CRF01-AE | 3 | V1 | I3 | C1 | ||||||
| A/G | 6 | I2 | I6 | I6 | S1, I1, N1 | |||||
| G/A/G | 2 | I2 | I2 | M1 | I2 | |||||
| G/K | 2 | I2 | I2 | P1 | ||||||
| D/G/D | 1 | I1 | ||||||||
| ?/K | 4 | I2, V2 | R1 | I3 | S1 | |||||
| Ub | 2 | I1, V1 | R2 | I1 | T1, V1 | |||||
| Group O | 4 | I2, V2 | C4 | I4 | P3, T1 | V4 | ||||
| Total | 142 | I17, V20 | M1/R15, I79, V2/C4 | F1 | I123 | I1 | P18, Other32 | V4 | I8 | I9 |
The letter represents the amino acid substitution, and the number indicates the number of strains with this mutation. Amino acids in boldface type are associated with resistance to PIs.
U, unknown subtypes.